Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma

BACKGROUND: The clonoSEQ® Assay (Adaptive Biotechnologies Corporation, Seattle, USA) identifies and tracks unique disease-associated immunoglobulin (Ig) sequences by next-generation sequencing of IgH, IgK, and IgL rearrangements and IgH-BCL1/2 translocations in malignant B cells. Here, we describe s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:BMC Cancer
Autors principals: Ching, Travers, Duncan, Megan E., Newman-Eerkes, Tera, McWhorter, Mollie M. E., Tracy, Jeffrey M., Steen, Michelle S., Brown, Ryan P., Venkatasubbarao, Srivatsa, Akers, Nicholas K., Vignali, Marissa, Moorhead, Martin E., Watson, Drew, Emerson, Ryan O., Mann, Tobias P., Cimler, B. Melina, Swatkowski, Pamela L., Kirsch, Ilan R., Sang, Charles, Robins, Harlan S., Howie, Bryan, Sherwood, Anna
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7325652/
https://ncbi.nlm.nih.gov/pubmed/32605647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07077-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars